Disparities in the Use of SGLT2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Adults With CKD in the United States
Hlavní autoři: | Susanne B. Nicholas, Radica Z. Alicic, Jenny Shen |
---|---|
Médium: | Článek |
Jazyk: | English |
Vydáno: |
Elsevier
2023-01-01
|
Edice: | Kidney Medicine |
On-line přístup: | http://www.sciencedirect.com/science/article/pii/S2590059522002230 |
Podobné jednotky
-
Disparities in SGLT2 Inhibitor or Glucagon-Like Peptide 1 Receptor Agonist Initiation Among Medicare-Insured Adults With CKD in the United StatesPlain-Language Summary
Autor: Julie Z. Zhao, a další
Vydáno: (2023-01-01) -
Hypoglycemia Risk With SGLT2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists Versus Sulfonylureas Among Medicare Insured Adults With CKD in the United StatesPlain-Language Summary
Autor: Julie Z. Zhao, a další
Vydáno: (2022-08-01) -
Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
Autor: Seungah Lee, a další
Vydáno: (2017-03-01) -
Glucagon‐like peptide‐1 receptor agonists and kidney outcomes
Autor: Richard J. MacIsaac, a další
Vydáno: (2024-10-01) -
Nephroprotective potential of glucagon-like peptide-1 receptor agonists
Autor: Minara S. Shamkhalova, a další
Vydáno: (2020-04-01)